Newer disease-modifying therapies (DMTs) are often used in pediatric multiple sclerosis (MS), and have similar short-term safety, tolerability, and side effect profiles as in adults, according to a recent study. Researchers conducted a cohort study including children with MS or clinically isolated syndrome (CIS) followed at 12 outpatient practices participating in the US Network of Pediatric MS Centers. DMT use, including duration, dose, and side effects, was analyzed. They found:
- As of July 2017, 1,019 pediatric patients with MS (n=748) or CIS (n= 71) were enrolled (65% female, mean onset 13.0 ± 3.9 years, mean follow-up 3.5 ± 3.1 years, median 1.6 visits per year).
- Of these, 78% (n=587) with MS and 11% (n=31) with CIS received DMT before age 18.
- This consisted of at least 1 newer DMT in 42%.
- Among 17%, the initial DMT prescribed was a newer agent.
- Over the last 10 years, the use of newer agents has increased, particularly in those ≥12 years and to lesser extent in those <12 years.
- The short-term side effect profiles of newer DMTs did not differ from those reported in adults.
Krysko KM, Graves J, Rensel M, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. [Published online ahead of print October 17, 2018]. Neurology. doi:10.1212/WNL.0000000000006471.